Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) as a cause of new-onset refractory status epilepticus (NORSE): Case report and review of literature

Abhishek Vaingankar; Ayush Agarwal; Divyani Garg; Pranjal Gupta; Ajay Garg; Divya M Radhakrishnan; Awadh K Pandit; Achal Kumar Srivastava

doi:10.1016/j.jneuroim.2025.578522

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) as a cause of new-onset refractory status epilepticus (NORSE): Case report and review of literature

J Neuroimmunol. 2025 Jan 8:399:578522. doi: 10.1016/j.jneuroim.2025.578522. Online ahead of print.

Authors

Abhishek Vaingankar¹, Ayush Agarwal², Divyani Garg¹, Pranjal Gupta³, Ajay Garg⁴, Divya M Radhakrishnan¹, Awadh K Pandit¹, Achal Kumar Srivastava¹

Affiliations

¹ Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
² Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: ayushthetaurian@gmail.com.
³ Department of Neurology, Wayne State University, Detroit, MI, USA.
⁴ Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India.

PMID: 39799767
DOI: 10.1016/j.jneuroim.2025.578522

Abstract

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare cause of NORSE. We describe the case of a young girl who presented with NORSE associated with MOGAD along with a systematic review of all cases of NORSE associated with MOGAD till date. Seizures associated with MOGAD are usually associated with good outcome but can occasionally be catastrophic and non-responsive to conventional therapies. Early initiation of anti-IL6 therapies might help improve outcomes in such patients.

Keywords: MOGAD; NORSE; Status epilepticus.